Investigations of new immune checkpoints and the development of targeted therapies against these markers are in progress, creating possibilities for more personalized and effective treatment strategies. Continuous research and robust clinical trials are needed to comprehend the complex dynamics of the Multiple Myeloma microenvironment to develop revolutionary therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Mandavkar et al. (2025) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: